P4802
Advantage of novel oral anticoagulants compared to vitamin-K antagonist in atrial fibrillation. Data from real world

Extract

Introduction: Patient adherence to chronic drug treatment has a great importance to avoid adverse events. Oral anticoagulant therapy decrease significantly the risk of stroke in atrial fibrillation (AF).

Aim: Our aim was to investigate the one year persistence of the newly started vitamin K antagonist (VKA) and novel oral anticoagulnts (NOACs) therapy in patients suffered from AF.

Patients and methods: We analysed the database of National Health Insurance Found in Hungary on pharmacy-claims

The study included data for patients who newly started (not administered oral anticoagulants [OACs] therapy before one year) VKA therapy (acenocumarol or warfarin) or NOACs tharapy (apixaban, dabigatran or rivaroxaban) in last quarter of year 2015. To model the persistence, the apparatus of survival analysis was used, where “survival” was the time to abandon the medication. As it was available to month precision, discrete time survival analysis was applied: a generalized linear model was estimated with complementary log-log link function with the kind of drug being the only explanatory variable. Treatment discontinuation was defined as a 60-day gap (grace period) with no medication coverage.